Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of NGM707 in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

NCT07511972 is registered in ClinicalTrials.gov with NGM Biopharmaceuticals, Inc as lead sponsor.

NCT NCT07511972
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07511972 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of NGM707 in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
Lead sponsor
NGM Biopharmaceuticals, Inc
Phase
Phase 2
Overall status
Withdrawn
Start date
November 14, 2023
Completion date
September 30, 2025
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

crc